Forecast for NINDS Exploratory Grant Program in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Research (P20 - Clinical Trial Optional)
ID: 359136Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359136
Timeline
    Description

    The National Institutes of Health (NIH) is set to announce a funding opportunity for the NINDS Exploratory Grant Program focused on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) research, utilizing the P20 activity code. This initiative aims to foster the establishment of new collaborative research teams to tackle pressing issues in ME/CFS, encouraging applications from investigators with relevant expertise, particularly those exploring post-infectious chronic illnesses. The estimated total program funding is $3 million, with approximately six awards expected, and interested applicants should prepare for the application process, which is anticipated to open with a synopsis posted on October 1, 2025, and close on February 25, 2026. For further inquiries, potential applicants can contact Dr. Vicky Whittemore at vicky.whittemore@nih.gov or by phone at 240-274-6696.

    Point(s) of Contact
    Vicky Whittemore, Ph.D. National Institute of Neurological Disorders and Stroke (NINDS)
    (240) 274-6696
    vicky.whittemore@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at enhancing the understanding of the neurological effects associated with infection-related chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This initiative encourages research projects that explore the neurological and psychiatric manifestations of these illnesses, with a particular interest in studies that may identify common neuropsychiatric mechanisms across multiple conditions, although applications focusing on individual illnesses are also welcome. The NOFO is anticipated to be released in Fall 2024, with applications due in Winter 2025, and will utilize the R21 grant mechanism. Interested applicants should prepare for a project start date expected in December 2025, with further details to be outlined in the forthcoming announcement.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Investigate Novel Therapeutic Interventions and Testing Strategies for Neurological Disorders Including to Treat, Modify and Prevent the Development of Epilepsy (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at investigating novel therapeutic interventions and testing strategies for neurological disorders, specifically targeting the treatment, modification, and prevention of epilepsy. This initiative encourages applicants to explore various intervention modalities and develop human-focused testing approaches, with a particular emphasis on preclinical therapy testing and model development. The total estimated program funding is $6.2 million, with individual awards ranging from $3.5 million to $4 million, and the application process is expected to open with a synopsis posted by December 19, 2025, closing on February 20, 2026. Interested applicants can reach out to Dr. Brian Klein at brian.klein@nih.gov or (301) 496-0981 for further information.
    Coccidioidomycosis Collaborative Research Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Coccidioidomycosis Collaborative Research Centers" aimed at advancing research to develop a vaccine for coccidioidomycosis, commonly known as Valley fever. This initiative seeks to support multi-disciplinary research centers that will address critical gaps in basic research, develop necessary tools and resources, and ultimately create a preventative vaccine for this serious fungal infection endemic to various regions in the United States. The grant is open to a wide range of eligible applicants, including Indian/Native American Tribal Governments, federal agencies, community-based organizations, and foreign institutions, with no cost-sharing or matching requirement. Interested parties can reach out to Dr. Dona Love at dona.love@nih.gov or by phone at 301-761-7788 for further information. The estimated synopsis post date is January 5, 2026, with a closing date for applications on March 6, 2026, and an anticipated award date of December 1, 2026.
    Centers of Excellence in Genomic Science (CEGS)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Centers of Excellence in Genomic Science (CEGS) program, aimed at fostering interdisciplinary research teams to tackle significant biomedical challenges from a genomics perspective. The initiative seeks to develop innovative concepts, methods, and technologies that can lead to transformative advancements in genomic science, genomic medicine, and computational genomics, with a focus on high-risk, high-reward projects that are unlikely to be pursued through standard funding mechanisms. With an estimated total program funding of $5 million and the expectation of awarding two grants, interested applicants can reach out to Stephanie A. Morris at morriss2@mail.nih.gov or call 301-435-5738 for further information. The application process is set to open with a synopsis posting on March 25, 2026, and will close on June 24, 2026, with awards anticipated by April 1, 2027.
    NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)" aimed at soliciting applications for research on exploratory and efficacy clinical trials that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS). This initiative will focus on evaluating various interventions, including drugs, biologics, devices, and therapies related to surgical, behavioral, and rehabilitation approaches. The opportunity is particularly significant for researchers with expertise in neurological disorders, as it encourages the development of meaningful collaborations and responsive projects in this critical health area. Interested applicants can reach out to Jeremy Brown, MD, via email at ExploratoryEfficacyTrials@ninds.nih.gov for further information, with the estimated synopsis posting date set for November 12, 2025, and applications expected to close by February 10, 2026.
    Forecast for The NINDS Human Biospecimen and Data Repository (U24 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the NINDS Human Biospecimen and Data Repository, aimed at advancing research in neurological disorders. This initiative will establish a repository to maintain and expand a collection of biospecimens, which will be made available to qualified academic and industry researchers to support basic, translational, and clinical research efforts. The total estimated funding for this program is $1,950,000, with one award anticipated, and interested applicants are encouraged to begin forming collaborations and developing proposals ahead of the expected synopsis posting on August 25, 2025. For further inquiries, potential applicants can contact Dr. Rebecca Price at rebecca.price@nih.gov or by phone at 301-827-3587.
    Research Program Award (R35 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Research Program Award (R35 Clinical Trial Optional) aimed at providing long-term support and flexibility for Program Directors (PDs) and Principal Investigators (PIs) in the field of neurological research. This grant, which does not require cost sharing or matching, is designed to alleviate the administrative burdens associated with managing multiple grant applications, allowing researchers to focus on their scientific endeavors and mentorship roles. The funding, with an award ceiling of $750,000 and a floor of $350,000, is intended to foster innovative research that aligns with the mission of the National Institute of Neurological Disorders and Stroke (NINDS). Interested applicants can reach out to Alisa Schaefer at nindsr35@ninds.nih.gov for further information, with the estimated synopsis posting date set for April 15, 2026, and a projected award date of March 1, 2027.
    Mechanistic Exploration of Therapeutic Targets and Treatable Traits to Improve CNS Outcomes in People with HIV
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanistic Exploration of Therapeutic Targets and Treatable Traits to Improve CNS Outcomes in People with HIV." This initiative aims to support research that identifies modifiable targets and mechanisms to alleviate central nervous system (CNS) complications in individuals living with HIV, leveraging patient-derived data and innovative model platforms. The program emphasizes the importance of understanding the multifactorial nature of CNS dysfunction and seeks to accelerate the development of effective interventions through clinical studies or pre-clinical models. The estimated total funding for this program is $3 million, with approximately six awards expected. Interested applicants, particularly those with expertise in systems biology and translational neurobiology, should prepare for the upcoming Notice of Funding Opportunity (NOFO), with applications anticipated to open in September 2025. For further inquiries, potential applicants can contact Vasudev R Rao at vasudev.rao@nih.gov or by phone at 301-825-3259.